AstraZeneca announced plans to build an end‑to‑end cell therapy manufacturing and innovation hub in Shanghai to support CAR‑T and next‑generation cell therapies across Asia, complementing prior deals and a $15 billion China commitment. The facility will include clinical manufacturing and an innovation center for early‑stage tools and regulatory support. Separately, Sartorius launched the Eveo Cell Therapy Platform—an integrated, modular system for autologous manufacturing that consolidates materials, production modules, software and QC assays to reduce vein‑to‑vein time and expand decentralized capacity. Both moves address chronic production bottlenecks by increasing regional capacity and enabling more parallelized, closed‑system manufacturing.